These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 33577365

  • 21. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C.
    J Urol; 2004 Aug; 172(2):529-32. PubMed ID: 15247721
    [Abstract] [Full Text] [Related]

  • 22. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM.
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [Abstract] [Full Text] [Related]

  • 23. Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.
    Planas Morin J, Celma Domenech A, Placer Santos J, Trilla Herrera E, Salvador Lacambra C, Lorente Garcia D, Regis L, Carles Galceran J, Morote Robles J.
    Rheumatol Int; 2014 Oct; 34(10):1419-25. PubMed ID: 24615021
    [Abstract] [Full Text] [Related]

  • 24. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
    Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS.
    J Clin Oncol; 2004 Jul 01; 22(13):2546-53. PubMed ID: 15226323
    [Abstract] [Full Text] [Related]

  • 25. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun 01; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.
    Pirl WF, Greer JA, Goode M, Smith MR.
    Psychooncology; 2008 Feb 01; 17(2):148-53. PubMed ID: 17443645
    [Abstract] [Full Text] [Related]

  • 30. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review.
    Datta M, Schwartz GG.
    Oncologist; 2012 Feb 01; 17(9):1171-9. PubMed ID: 22836449
    [Abstract] [Full Text] [Related]

  • 31. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.
    Int J Urol; 2007 Dec 01; 14(12):1071-5. PubMed ID: 18036042
    [Abstract] [Full Text] [Related]

  • 32. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S, Puntus T.
    Wien Med Wochenschr; 2012 Sep 01; 162(17-18):380-5. PubMed ID: 22875632
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep 01; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH, Gluck C, Kiger WS, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I.
    Urol Oncol; 2008 Sep 01; 26(4):372-7. PubMed ID: 18367113
    [Abstract] [Full Text] [Related]

  • 39. Management of treatment-related osteoporosis in men with prostate cancer.
    Smith MR.
    Cancer Treat Rev; 2003 Jun 01; 29(3):211-8. PubMed ID: 12787715
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.